Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Apertus Pharmaceuticals is a pharmaceutical R&D and contract manufacturing provider based in Missouri, USA, founded in 2012. According to its website, the company began with API development and has expanded into formulation development, analytical development, and small-scale cGMP drug manufacturing. Note that this is not a SaaS or enterprise software product: in this context, API refers to active pharmaceutical ingredient, not a software interface.
Apertus offers service modules including API Services, Formulation Development, Contract Manufacturing, and Analytical Development. Its formulation development experience covers sterile injectables, highly potent formulations, nasal sprays, DEA-regulated products, topical creams, liquids, tablets, capsules, suppositories, and more. For contract manufacturing, the company focuses on suppositories, capsules, tablets, and topical products, and can produce small- to mid-scale prescription drug batches at its FDA-inspected Saint Louis facility. The website also mentions cGMP manufacturing capabilities, DEA manufacturing registration, and research and analytical registrations.
The website does not disclose packages, pricing, payment methods, or service timelines. Given the nature of the business, Apertus is more likely to use project-based or contract-based quotes, with pricing depending on the drug type, dosage form, development stage, batch size, compliance requirements, and the complexity of analytical methods.
Its strengths include a solid team track record, with management backgrounds in fine chemicals, pharmaceuticals, biotechnology, regulatory affairs, and law; a service chain spanning APIs through formulations and manufacturing; and FDA inspection history with disclosed remediation notes. The main drawbacks are limited public information, with no customer case studies, quality system documents, capacity parameters, equipment lists, delivery SLAs, or pricing mechanism available. From a SaaS evaluation perspective, there is also no information on third-party integrations, permission management, software APIs, cloud deployment, or data security features.
Apertus is better suited to early-stage pharmaceutical companies, biotechnology firms, university research teams, or drug development projects that need small- to mid-scale cGMP manufacturing support, especially customers requiring assistance with APIs, regulated products, formulation development, and analytical methods.
The available website text does not state whether the site is accessible from mainland China, so it is not possible to determine whether direct access works. Actual access testing is recommended, along with email confirmation regarding cross-border collaboration, quality audits, and logistics compliance requirements.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on apertuspharma.com official site.
apertuspharma.com is an Unknown SaaS provider. TG4G tracks its product information, an overall rating of 5.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach apertuspharma.com directly.